Zydus Lifesciences Targets FY26 Expansion Amid Slower US Growth Post-Revlimid Peak

Zydus Lifesciences Ltd. has outlined its FY26 expansion strategy, aiming for double-digit revenue growth, despite slower momentum in the US market following the peak sales of its blockbuster generic drug Revlimid.

Key Financial Highlights & Growth Strategy

• FY25 Revenue: ₹23,240 crore, marking a 19% YoY increase.
• EBITDA Margin: 30.4% in FY25, projected to exceed 26% in FY26.
• US Market Outlook: Expected single-digit growth due to tapering Revlimid sales and rising competition.
• India & International Markets: Anticipated strong growth, driven by biologics, vaccines, and medtech.

Pipeline & Expansion Plans

Zydus is banking on 14–15 critical launches in FY27, including complex generics with semi-exclusive opportunities to sustain its US business above a $1 billion base. The company is also scaling up its anti-diabetes Sitagliptin franchise, secured by a five-year national contract.

Market Reaction & Investor Sentiment

Despite the slower US growth, Zydus remains optimistic about its global expansion, particularly in emerging markets and Europe. The company’s consumer wellness segment delivered industry-leading double-digit growth in FY25, a trend expected to continue.

With strategic diversification and a robust product pipeline, Zydus Lifesciences is positioning itself for sustained growth in FY26 and beyond.

For more updates on pharmaceutical trends and corporate earnings, stay tuned!